1. Scrip

Pipeline, Commercial Needs Drive Active China Licensing Scene In July

 
• By Dexter Jie Yan

July was an active month for deals between Chinese biopharma firms, as some looked to build their pipelines and others for partners to help commercialize products moving to market. Two ADCs, a GLP-1R/GIPR fusion protein and an IL-4Rα antibody were among the assets changing hands.

deal spike
July saw a surge in domestic partnerships for homegrown novel drugs in China • Source: Shutterstock

Domestic licensing deals for homegrown innovative drugs in China posted a spike in July, as drug makers with established commercialization capabilities replenished their late-stage pipelines and research-focused firms turned away from building their own sales teams to conserve cash.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia